467 related articles for article (PubMed ID: 23040437)
21. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R
Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245
[TBL] [Abstract][Full Text] [Related]
22. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Martin TG
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Berdeja JG; Gregory TK; Faber EA; Hart LL; Mace JR; Arrowsmith ER; Flinn IW; Matous JV
Am J Hematol; 2021 Apr; 96(4):428-435. PubMed ID: 33421178
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Lendvai N; Hilden P; Devlin S; Landau H; Hassoun H; Lesokhin AM; Tsakos I; Redling K; Koehne G; Chung DJ; Schaffer WL; Giralt SA
Blood; 2014 Aug; 124(6):899-906. PubMed ID: 24963043
[TBL] [Abstract][Full Text] [Related]
25. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
26. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
[TBL] [Abstract][Full Text] [Related]
27. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
28. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
[TBL] [Abstract][Full Text] [Related]
29. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.
Berenson JR; Hilger JD; Yellin O; Dichmann R; Patel-Donnelly D; Boccia RV; Bessudo A; Stampleman L; Gravenor D; Eshaghian S; Nassir Y; Swift RA; Vescio RA
Leukemia; 2014 Jul; 28(7):1529-36. PubMed ID: 24429497
[TBL] [Abstract][Full Text] [Related]
30. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
31. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F
Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268
[TBL] [Abstract][Full Text] [Related]
33. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
34. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
35. A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Daniely D; Forouzan E; Spektor TM; Cohen A; Bitran JD; Chen G; Moezi MM; Bessudo A; Hrom J; Eshaghian S; Swift RA; Eades BM; Kim C; Lim S; Berenson JR
Exp Hematol; 2022 Jul; 111():79-86. PubMed ID: 35417741
[TBL] [Abstract][Full Text] [Related]
36. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
37. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Nooka AK
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
[TBL] [Abstract][Full Text] [Related]
38. Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.
Takezako N; Shibayama H; Handa H; Hagiwara S; Ozaki S; Suzuki K; Kosugi H; Ri M; Sugiura I; Choi I; Miyamoto T; Iida S
Int J Hematol; 2021 Feb; 113(2):219-230. PubMed ID: 33037990
[TBL] [Abstract][Full Text] [Related]
39. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
